Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00498966 · ClinicalTrials.gov registry record · Phase 2
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
A Phase 2 study, sponsored by AEterna Zentaris.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00498966 is a Phase 2 study that has completed, run by AEterna Zentaris. The registered enrollment target is 50 participants.
The verdict
NCT00498966, a Phase 2 study, has completed, sponsored by AEterna Zentaris.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a Phase II study. Patients with kidney carcinoma will be considered in two groups. The goals of this study are: * To measure clinical benefit defined as tumor response or progression-free survival for more than 12 weeks in patients with metastatic carcinoma of the kidney who have failed or have progressed on a VEGF receptor inhibitor * To evaluate the safety of perifosine in patients with metastatic carcinoma of the kidney who have failed or have progressed on a VEGF receptor inhibitor
Interventions
- DRUG Perifosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00498966
The ClinicalTrials.gov registry entry for NCT00498966 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AEterna Zentaris, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Perifosine is the first listed.
NCT00498966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00498966 about?
NCT00498966 is a clinical study titled "Ph II Study of Perifosine for Patients With Carcinoma of the Kidney". This is a Phase II study. Patients with kidney carcinoma will be considered in two groups. The goals of this study are: * To measure clinical benefit defined as tumor response or progression-free survival for more than 12 weeks in patients with metastatic carcinoma of the kidney who have failed or ...
What is the current status of trial NCT00498966?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2007-07. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00498966?
The interventions under investigation include: Perifosine (DRUG).
Who is sponsoring clinical trial NCT00498966?
This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.